Výsledky vyhledávání - "Sodium-Glucose Transporter 2 Inhibitors/adverse effects"

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction Autor Solomon, Scott D., McMurray, John J.V., Claggett, Brian, de Boer, Rudolf A., DeMets, David, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe, Shah, Sanjiv J., Desai, Akshay S., Jhund, Pardeep S., Belohlavek, Jan, Chiang, Chern-En, Borleffs, C. Jan Willem, Comin-Colet, Josep, Dobreanu, Dan, Drozdz, Jaroslaw, Fang, James C., Alcocer-Gamba, Marco Antonio, Al Habeeb, Waleed, Han, Yaling, Cabrera Honorio, Jose Walter, Janssens, Stefan P., Katova, Tzvetana, Kitakaze, Masafumi, Merkely, Béla, O’Meara, Eileen, Saraiva, Jose Francisco Kerr, Tereshchenko, Sergey N., Thierer, Jorge, Vaduganathan, Muthiah, Vardeny, Orly, Verma, Subodh, Pham, Vinh Nguyen, Wilderäng, Ulrica, Zaozerska, Natalia, Bachus, Erasmus, Lindholm, Daniel, Petersson, Magnus, Langkilde, Anna Maria

“…In a trial involving patients with heart failure and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of worsening heart failure…”
Získat plný text

Empagliflozin in Patients with Chronic Kidney Disease Autor Herrington, William G, Staplin, Natalie, Wanner, Christoph, Green, Jennifer B, Hauske, Sibylle J, Emberson, Jonathan R, Preiss, David, Judge, Parminder, Mayne, Kaitlin J, Ng, Sarah Y A, Sammons, Emily, Zhu, Doreen, Hill, Michael, Stevens, Will, Wallendszus, Karl, Brenner, Susanne, Cheung, Alfred K, Liu, Zhi-Hong, Li, Jing, Hooi, Lai Seong, Liu, Wen, Kadowaki, Takashi, Nangaku, Masaomi, Levin, Adeera, Cherney, David, Maggioni, Aldo P, Pontremoli, Roberto, Deo, Rajat, Goto, Shinya, Rossello, Xavier, Tuttle, Katherine R, Steubl, Dominik, Petrini, Michaela, Massey, Dan, Eilbracht, Jens, Brueckmann, Martina, Landray, Martin J, Baigent, Colin, Haynes, Richard

“…In this trial involving patients with chronic kidney disease, empagliflozin resulted in a lower risk of disease progression or death from cardiovascular causes…”
Získat plný text

Empagliflozin in Heart Failure with a Preserved Ejection Fraction Autor Anker, Stefan D, Butler, Javed, Filippatos, Gerasimos, Ferreira, João P, Bocchi, Edimar, Böhm, Michael, Brunner–La Rocca, Hans-Peter, Choi, Dong-Ju, Chopra, Vijay, Chuquiure-Valenzuela, Eduardo, Giannetti, Nadia, Gomez-Mesa, Juan Esteban, Janssens, Stefan, Januzzi, James L, Gonzalez-Juanatey, Jose R, Merkely, Bela, Nicholls, Stephen J, Perrone, Sergio V, Piña, Ileana L, Ponikowski, Piotr, Senni, Michele, Sim, David, Spinar, Jindrich, Squire, Iain, Taddei, Stefano, Tsutsui, Hiroyuki, Verma, Subodh, Vinereanu, Dragos, Zhang, Jian, Carson, Peter, Lam, Carolyn Su Ping, Marx, Nikolaus, Zeller, Cordula, Sattar, Naveed, Jamal, Waheed, Schnaidt, Sven, Schnee, Janet M, Brueckmann, Martina, Pocock, Stuart J, Zannad, Faiez, Packer, Milton

“…In a randomized trial, 5988 patients with heart failure with preserved ejection fraction were assigned to receive either empagliflozin or placebo in addition…”
Získat plný text

Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF) Autor Schulze, P Christian, Bogoviku, Jürgen, Westphal, Julian, Aftanski, Pawel, Haertel, Franz, Grund, Sissy, von Haehling, Stephan, Schumacher, Ulrike, Möbius-Winkler, Sven, Busch, Martin

“…Effective diuretic regimens using loop diuretics in patients with acute decompensated heart failure are often limited by the development of worsening kidney…”
Zjistit podrobnosti o přístupu

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials Autor Baigent, Colin, Emberson, JonathanR, Haynes, Richard, Herrington, William G., Judge, Parminder, Landray, Martin J., Mayne, Kaitlin J., Ng, Sarah Y.A., Preiss, David, Roddick, Alistair J., Staplin, Natalie, Zhu, Doreen, Anker, Stefan D., Bhatt, Deepak L., Brueckmann, Martina, Butler, Javed, Cherney, David Z.I., Green, Jennifer B., Hauske, Sibylle J., Heerspink, Hiddo J.L., Inzucchi, Silvio E., Jardine, Meg J., Liu, Chih-Chin, Mahaffey, Kenneth W., McCausland, Finnian R., McGuire, Darren K., McMurray, John J.V., Neal, Bruce, Neuen, Brendon L., Packer, Milton, Perkovic, Vlado, Sabatine, Marc S., Solomon, Scott D., Vaduganathan, Muthiah, Wanner, Christoph, Wheeler, David C., Wiviott, Stephen D., Zannad, Faiez

“…Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with…”
Získat plný text

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure Autor Packer, Milton, Anker, Stefan D, Butler, Javed, Filippatos, Gerasimos, Pocock, Stuart J, Carson, Peter, Januzzi, James, Verma, Subodh, Tsutsui, Hiroyuki, Brueckmann, Martina, Jamal, Waheed, Kimura, Karen, Schnee, Janet, Zeller, Cordula, Cotton, Daniel, Bocchi, Edimar, Böhm, Michael, Choi, Dong-Ju, Chopra, Vijay, Chuquiure, Eduardo, Giannetti, Nadia, Janssens, Stefan, Zhang, Jian, Gonzalez Juanatey, Jose R, Kaul, Sanjay, Brunner-La Rocca, Hans-Peter, Merkely, Bela, Nicholls, Stephen J, Perrone, Sergio, Pina, Ileana, Ponikowski, Piotr, Sattar, Naveed, Senni, Michele, Seronde, Marie-France, Spinar, Jindrich, Squire, Iain, Taddei, Stefano, Wanner, Christoph, Zannad, Faiez

“…Among patients with heart failure and a reduced ejection fraction, those who received the SGLT2 inhibitor empagliflozin had a significantly lower incidence of…”
Získat plný text

Dapagliflozin in Patients with Chronic Kidney Disease Autor Heerspink, Hiddo J.L, Stefánsson, Bergur V, Correa-Rotter, Ricardo, Chertow, Glenn M, Greene, Tom, Hou, Fan-Fan, Mann, Johannes F.E, McMurray, John J.V, Lindberg, Magnus, Rossing, Peter, Sjöström, C. David, Toto, Roberto D, Langkilde, Anna-Maria, Wheeler, David C

“…In this trial, patients with CKD (with or without type 2 diabetes) were randomly assigned to receive dapagliflozin or placebo. The primary composite outcome —…”
Získat plný text

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure Autor Bhatt, Deepak L, Szarek, Michael, Steg, P. Gabriel, Cannon, Christopher P, Leiter, Lawrence A, McGuire, Darren K, Lewis, Julia B, Riddle, Matthew C, Voors, Adriaan A, Metra, Marco, Lund, Lars H, Komajda, Michel, Testani, Jeffrey M, Wilcox, Christopher S, Ponikowski, Piotr, Lopes, Renato D, Verma, Subodh, Lapuerta, Pablo, Pitt, Bertram

“…Patients with diabetes and recent worsening heart failure that had led to hospitalization were randomly assigned to receive sotagliflozin or placebo. At a…”
Získat plný text

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial Autor Voors, Adriaan A., Angermann, Christiane E., Teerlink, John R., Collins, Sean P., Kosiborod, Mikhail, Biegus, Jan, Ferreira, João Pedro, Nassif, Michael E., Psotka, Mitchell A., Tromp, Jasper, Borleffs, C. Jan Willem, Ma, Changsheng, Comin-Colet, Joseph, Fu, Michael, Janssens, Stefan P., Kiss, Robert G., Mentz, Robert J., Sakata, Yasushi, Schirmer, Henrik, Schou, Morten, Schulze, P. Christian, Spinarova, Lenka, Volterrani, Maurizio, Wranicz, Jerzy K., Zeymer, Uwe, Zieroth, Shelley, Brueckmann, Martina, Blatchford, Jonathan P., Salsali, Afshin, Ponikowski, Piotr

“…The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic…”
Získat plný text

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction Autor McMurray, John J.V, Solomon, Scott D, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, Sabatine, Marc S, Anand, Inder S, Bělohlávek, Jan, Böhm, Michael, Chiang, Chern-En, Chopra, Vijay K, de Boer, Rudolf A, Desai, Akshay S, Diez, Mirta, Drozdz, Jaroslaw, Dukát, Andrej, Ge, Junbo, Howlett, Jonathan G, Katova, Tzvetana, Kitakaze, Masafumi, Ljungman, Charlotta E.A, Merkely, Béla, Nicolau, Jose C, O’Meara, Eileen, Petrie, Mark C, Vinh, Pham N, Schou, Morten, Tereshchenko, Sergey, Verma, Subodh, Held, Claes, DeMets, David L, Docherty, Kieran F, Jhund, Pardeep S, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna-Maria

“…In this randomized, placebo-controlled trial, investigators evaluated the effects of the sodium–glucose cotransporter 2 inhibitor dapagliflozin in patients…”
Získat plný text

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease Autor Bhatt, Deepak L, Szarek, Michael, Pitt, Bertram, Cannon, Christopher P, Leiter, Lawrence A, McGuire, Darren K, Lewis, Julia B, Riddle, Matthew C, Inzucchi, Silvio E, Kosiborod, Mikhail N, Cherney, David Z.I, Dwyer, Jamie P, Scirica, Benjamin M, Bailey, Clifford J, Díaz, Rafael, Ray, Kausik K, Udell, Jacob A, Lopes, Renato D, Lapuerta, Pablo, Steg, P. Gabriel

“…In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes,…”
Získat plný text

Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Autor Shi, Qingyang, Nong, Kailei, Vandvik, Per Olav, Guyatt, Gordon H, Schnell, Oliver, Rydén, Lars, Marx, Nikolaus, Brosius, Frank C, Mustafa, Reem A, Agarwal, Arnav, Zou, Xinyu, Mao, Yunhe, Asadollahifar, Aminreza, Chowdhury, Saifur Rahman, Zhai, Chunjuan, Gupta, Sana, Gao, Ya, Lima, João Pedro, Numata, Kenji, Qiao, Zhi, Fan, Qinlin, Yang, Qinbo, Jin, Yinghui, Ge, Long, Yang, Qiuyu, Zhu, Hongfei, Yang, Fan, Chen, Zhe, Lu, Xi, He, Siyu, Chen, Xiangyang, Lyu, Xiafei, An, Xingxing, Chen, Yaolong, Hao, Qiukui, Standl, Eberhard, Siemieniuk, Reed, Agoritsas, Thomas, Tian, Haoming, Li, Sheyu

“…AbstractObjectiveTo compare the benefits and harms of drug treatments for adults with type 2 diabetes, adding non-steroidal mineralocorticoid receptor…”
Získat plný text

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy Autor Perkovic, Vlado, Jardine, Meg J, Neal, Bruce, Bompoint, Severine, Heerspink, Hiddo J.L, Charytan, David M, Edwards, Robert, Agarwal, Rajiv, Bakris, George, Bull, Scott, Cannon, Christopher P, Capuano, George, Chu, Pei-Ling, de Zeeuw, Dick, Greene, Tom, Levin, Adeera, Pollock, Carol, Wheeler, David C, Yavin, Yshai, Zhang, Hong, Zinman, Bernard, Meininger, Gary, Brenner, Barry M, Mahaffey, Kenneth W

“…This double-blind, randomized trial compared canagliflozin with placebo in patients with type 2 diabetes and evidence of kidney disease that was treated with…”
Získat plný text

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria Autor Neuen, Brendon L, Heerspink, Hiddo J L, Vart, Priya, Claggett, Brian L, Fletcher, Robert A, Arnott, Clare, de Oliveira Costa, Julianna, Falster, Michael O, Pearson, Sallie-Anne, Mahaffey, Kenneth W, Neal, Bruce, Agarwal, Rajiv, Bakris, George, Perkovic, Vlado, Solomon, Scott D, Vaduganathan, Muthiah

“…Sodium glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the nonsteroidal mineralocorticoid receptor…”
Zjistit podrobnosti o přístupu

Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials Autor Neuen, Brendon L, Oshima, Megumi, Agarwal, Rajiv, Arnott, Clare, Cherney, David Z, Edwards, Robert, Langkilde, Anna Maria, Mahaffey, Kenneth W, McGuire, Darren K, Neal, Bruce, Perkovic, Vlado, Pong, Annpey, Sabatine, Marc S, Raz, Itamar, Toyama, Tadashi, Wanner, Christoph, Wheeler, David C, Wiviott, Stephen D, Zinman, Bernard, Heerspink, Hiddo J L

“…Hyperkalemia increases risk of cardiac arrhythmias and death and limits the use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid…”
Zjistit podrobnosti o přístupu

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice Autor Oshima, Megumi, Jardine, Meg J, Agarwal, Rajiv, Bakris, George, Cannon, Christopher P, Charytan, David M, de Zeeuw, Dick, Edwards, Robert, Greene, Tom, Levin, Adeera, Lim, Soo Kun, Mahaffey, Kenneth W, Neal, Bruce, Pollock, Carol, Rosenthal, Norman, Wheeler, David C, Zhang, Hong, Zinman, Bernard, Perkovic, Vlado, Heerspink, Hiddo J L

“…Canagliflozin slows the progression of chronic kidney disease in patients with type 2 diabetes and induces a reversible acute drop in estimated glomerular…”
Zjistit podrobnosti o přístupu

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial Autor Nassif, Michael E., Windsor, Sheryl L., Borlaug, Barry A., Kitzman, Dalane W., Shah, Sanjiv J., Tang, Fengming, Khariton, Yevgeniy, Malik, Ali O., Khumri, Taiyeb, Umpierrez, Guillermo, Lamba, Sumant, Sharma, Kavita, Khan, Sadiya S., Chandra, Lokesh, Gordon, Robert A., Ryan, John J., Chaudhry, Sunit-Preet, Joseph, Susan M., Chow, Chen H., Kanwar, Manreet K., Pursley, Michael, Siraj, Elias S., Lewis, Gregory D., Clemson, Barry S., Fong, Michael, Kosiborod, Mikhail N.

“…Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life…”
Získat plný text

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Autor Palmer, Suetonia C, Tendal, Britta, Mustafa, Reem A, Vandvik, Per Olav, Li, Sheyu, Hao, Qiukui, Tunnicliffe, David, Ruospo, Marinella, Natale, Patrizia, Saglimbene, Valeria, Nicolucci, Antonio, Johnson, David W, Tonelli, Marcello, Rossi, Maria Chiara, Badve, Sunil V, Cho, Yeoungjee, Nadeau-Fredette, Annie-Claire, Burke, Michael, Faruque, Labib I, Lloyd, Anita, Ahmad, Nasreen, Liu, Yuanchen, Tiv, Sophanny, Millard, Tanya, Gagliardi, Lucia, Kolanu, Nithin, Barmanray, Rahul D, McMorrow, Rita, Raygoza Cortez, Ana Karina, White, Heath, Chen, Xiangyang, Zhou, Xu, Liu, Jiali, Rodríguez, Andrea Flores, González-Colmenero, Alejandro Díaz, Wang, Yang, Li, Ling, Sutanto, Surya, Solis, Ricardo Cesar, Díaz González-Colmenero, Fernando, Rodriguez-Gutierrez, René, Walsh, Michael, Guyatt, Gordon, Strippoli, Giovanni F M

“…AbstractObjectiveTo evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2…”
Získat plný text

Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy Autor Palmer, Biff F, Clegg, Deborah J

“…Sodium-glucose cotransporter-2 (SGLT2) inhibitors are drugs designed to lower plasma glucose concentration by inhibiting Na -glucose-coupled transport in the…”
Zjistit podrobnosti o přístupu

Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry Autor Paolisso, Pasquale, Bergamaschi, Luca, Gragnano, Felice, Gallinoro, Emanuele, Cesaro, Arturo, Sardu, Celestino, Mileva, Niya, Foà, Alberto, Armillotta, Matteo, Sansonetti, Angelo, Amicone, Sara, Impellizzeri, Andrea, Esposito, Giuseppe, Morici, Nuccia, Andrea, Oreglia Jacopo, Casella, Gianni, Mauro, Ciro, Vassilev, Dobrin, Galie, Nazzareno, Santulli, Gaetano, Marfella, Raffaele, Calabrò, Paolo, Pizzi, Carmine, Barbato, Emanuele

“…To investigate in-hospital and long-term prognosis in T2DM patients presenting with acute myocardial infarction (AMI) treated with SGLT2-I versus other oral…”
Získat plný text